What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2020-08-05 compared with 2020-05-08 · 34 added, 16 removed, 21 unchanged (70% of the section changed)

Other Information

On July 30, 2020, Kamran Alam, CPA, MBA, the Company’s Senior Vice President-Finance and Principal Financial Officer resigned his position as Principal Financial Officer of Rocket.

Alam’s resignation is not the result of any dispute or disagreement with the Company, or any matter relating to the Company's accounting practices or financial statements.

On July 30, 2020, the Company’s Board of Directors appointed John Militello, CPA, the Company’s current Senior Controller, Treasurer and Principal Accounting Officer as the Company’s Vice President of Finance, Senior Controller, Treasurer and Principal Financial and Accounting Officer, effective immediately.

Militello was previously the Company’s Principal Financial and Accounting Officer from January 2018 to October 2019 and the Company’s Principal Accounting Officer from October 2019 to present.

Militello, age 46, worked at Immune Pharmaceuticals, Inc., a publicly traded biotechnology company, where he most recently served as Vice President of Finance (principal financial and accounting officer), Controller and Chief Accounting Officer.

Prior to that, Mr.

Militello was an Assistant Controller with Retrophin, Inc., a San Diego based biotech company, and the Manager, External Reporting & Compliance at Volt Information Sciences, Inc., a billion dollar, multi-national publicly traded staffing company.

Prior to Volt Information Sciences, Inc., Mr.

Militello was a Senior Manager with BDO USA, LLP serving multi-national SEC registrants and was a member of the Life Sciences practice group.

Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St.

Joseph’s College.

There are no family relationships between Mr.

Militello , on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other.

There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr.

Militello , on the one hand, and the Company, on the other.

Description of Exhibit

Agreement and Plan of Merger and Reorganization, dated as of September 12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd.

and Rome Merger Sub (incorporated by reference to Exhibit 2.1 to the Company’s

Current Report on Form 8-K (001-36829), filed with the SEC on September 13, 2017)

Seventh Amended and Restated Certificate of Incorporation of Rocket Pharmaceuticals, Inc., effective as of February 23, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K (001-36829), filed with the

SEC on March 31, 2015)

Certificate of Amendment (Reverse Stock Split) to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective as of January 4, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on

Form 8-K (001-36829), filed with the SEC on January 5, 2018)

Certificate of Amendment (Name Change) to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective January 4, 2018 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K

(001-36829), filed with the SEC on January 5, 2018)

Certificate of Amendment to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective as of June 25, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36829),

filed with the SEC on June 25, 2018)

Amended and Restated By-Laws of Rocket Pharmaceuticals, Inc., effective as of March 29, 2018 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (001-36829), filed with the SEC on April 4, 2018)

Agreement and Plan of Merger and Reorganization, dated as of September 12, 2017, by and among Inotek Pharmaceuticals Corporation,

Rocket Pharmaceuticals, Ltd.

and Rome Merger Sub (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (001-36829), filed with the SEC on September 13, 2017)

Seventh Amended and Restated Certificate of Incorporation of Rocket Pharmaceuticals, Inc., effective as of February 23, 2015(incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K (001-36829), filed with the SEC on March 31, 2015)

Amended and Restated By-Laws of Rocket Pharmaceuticals, Inc., effective as of March 29, 2018 (incorporated by reference to Exhibit

3.2 to the Company’s Current Report on Form 8-K (001-36829), filed with the SEC on April 4, 2018)

Amendment to First Supplemental Indenture, dated as of February 18, 2020, between Rocket Pharmaceuticals, Inc.

and Wilmington Trust, National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Company’s Current Report

on Form 8-K (001-36829), filed with the SEC on February 20, 2020)

and Wilmington

Trust, National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K (001-36829), filed with the SEC on February 20, 2020)

Form of Exchange Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (001-36829), filed with the SEC on February 11, 2020)

Consulting Agreement between the Registrant and Gotham Makker, MD, dated June 16, 2020.

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

11 unchanged sentences

ROCKET PHARMACEUTICALS, INC.

August 5, 2020

/s/ Gaurav Shah, MD

2 unchanged sentences

(Principal Executive Officer)

/s/ Kamran Alam

(Principal Financial Officer)

August 5, 2020

/s/ John Militello

John Militello,

VP, Finance, Sr.

Controller and Treasurer

(Principal Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information